Invitation to conference call and webcast
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) is conducting an analyst and investor conference call/webcast today, 9th January 2017, at 15.00 CET, to present further financial aspects of the acquired oncology programs from TetraLogic Pharmaceuticals Corporation, including the clinical stage compounds remetinostat and birinapant. Niklas Prager CEO, Ola Burmark CFO and Richard Bethell CSO will be presenting and will be available for questions. To join the conference call, please dial:Sweden +46 (0)8 566 426 62Europe +44(0)20 300 898 02USA +1 855 753 22 35 The